Rhumbline Advisers Ligand Pharmaceuticals Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 60,020 shares of LGND stock, worth $7.34 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
60,020
Previous 61,332 2.14%
Holding current value
$7.34 Million
Previous $5.17 Million 16.35%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$82.7 - $110.11 $108,502 - $144,464
-1,312 Reduced 2.14%
60,020 $6.01 Million
Q2 2024

Aug 01, 2024
BUY
$68.53 - $87.91 $73,806 - $94,679
1,077 Added 1.79%
61,332 $5.17 Million
Q1 2024

May 09, 2024
BUY
$68.64 - $89.2 $50,107 - $65,116
730 Added 1.23%
60,255 $4.4 Million
Q4 2023

Feb 08, 2024
BUY
$49.57 - $72.63 $118,868 - $174,166
2,398 Added 4.2%
59,525 $4.25 Million
Q3 2023

Nov 09, 2023
BUY
$58.86 - $72.67 $95,824 - $118,306
1,628 Added 2.93%
57,127 $3.42 Million
Q2 2023

Aug 08, 2023
BUY
$69.53 - $79.33 $170,904 - $194,993
2,458 Added 4.63%
55,499 $4 Million
Q1 2023

May 11, 2023
BUY
$65.67 - $77.08 $153,799 - $180,521
2,342 Added 4.62%
53,041 $3.9 Million
Q4 2022

Feb 14, 2023
BUY
$61.72 - $96.74 $135,290 - $212,054
2,192 Added 4.52%
50,699 $3.39 Million
Q3 2022

Nov 10, 2022
BUY
$0.01 - $107.56 $6 - $71,312
663 Added 1.39%
48,507 $4.18 Million
Q2 2022

Aug 11, 2022
BUY
$74.52 - $117.06 $135,402 - $212,698
1,817 Added 3.95%
47,844 $4.27 Million
Q1 2022

May 12, 2022
BUY
$94.99 - $151.56 $97,269 - $155,197
1,024 Added 2.28%
46,027 $5.18 Million
Q4 2021

Feb 10, 2022
SELL
$127.69 - $165.85 $154,249 - $200,346
-1,208 Reduced 2.61%
45,003 $6.95 Million
Q3 2021

Nov 12, 2021
SELL
$102.33 - $144.73 $451,377 - $638,404
-4,411 Reduced 8.71%
46,211 $6.44 Million
Q2 2021

Aug 05, 2021
BUY
$113.03 - $155.64 $577,244 - $794,853
5,107 Added 11.22%
50,622 $6.64 Million
Q1 2021

May 06, 2021
SELL
$99.52 - $215.83 $28,960 - $62,806
-291 Reduced 0.64%
45,515 $6.94 Million
Q4 2020

Feb 10, 2021
BUY
$80.55 - $106.05 $1,288 - $1,696
16 Added 0.03%
45,806 $4.56 Million
Q3 2020

Nov 12, 2020
SELL
$89.56 - $126.72 $796,904 - $1.13 Million
-8,898 Reduced 16.27%
45,790 $4.37 Million
Q2 2020

Aug 13, 2020
SELL
$68.28 - $123.65 $525,482 - $951,610
-7,696 Reduced 12.34%
54,688 $6.12 Million
Q1 2020

May 06, 2020
SELL
$63.37 - $107.88 $21,609 - $36,787
-341 Reduced 0.54%
62,384 $4.54 Million
Q4 2019

Feb 05, 2020
SELL
$96.94 - $113.59 $296,248 - $347,131
-3,056 Reduced 4.65%
62,725 $6.54 Million
Q3 2019

Oct 23, 2019
SELL
$86.25 - $120.16 $52,785 - $73,537
-612 Reduced 0.92%
65,781 $6.55 Million
Q2 2019

Aug 14, 2019
SELL
$107.38 - $129.34 $87,622 - $105,541
-816 Reduced 1.21%
66,393 $7.58 Million
Q1 2019

May 01, 2019
SELL
$105.93 - $142.47 $40,465 - $54,423
-382 Reduced 0.57%
67,209 $8.45 Million
Q4 2018

Jan 31, 2019
BUY
$128.36 - $272.13 $2.04 Million - $4.33 Million
15,915 Added 30.8%
67,591 $9.17 Million
Q3 2018

Nov 07, 2018
SELL
$211.18 - $274.49 $395,328 - $513,845
-1,872 Reduced 3.5%
51,676 $14.2 Million
Q2 2018

Aug 06, 2018
BUY
$150.77 - $207.98 $333,955 - $460,675
2,215 Added 4.31%
53,548 $11.1 Million
Q1 2018

May 02, 2018
BUY
$138.63 - $182.62 $86,366 - $113,772
623 Added 1.23%
51,333 $8.48 Million
Q4 2017

Feb 09, 2018
BUY
$128.36 - $147.04 $923,165 - $1.06 Million
7,192 Added 16.53%
50,710 $6.94 Million
Q3 2017

Nov 06, 2017
BUY
$120.91 - $137.94 $5.26 Million - $6 Million
43,518
43,518 $5.93 Million

Others Institutions Holding LGND

# of Institutions
257
Shares Held
18.2M
Call Options Held
26.8K
Put Options Held
9.3K
View Full List

About LIGAND PHARMACEUTICALS INC

LGND Quotes by TradingView
  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $2.07B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email